Source:

Press Release

Disclosures: Quartel is chief medical officer of Adamas Pharmaceuticals.
February 02, 2021
1 min read
Save

Gocovri receives FDA approval for second indication in Parkinson’s disease

Source:

Press Release

Disclosures: Quartel is chief medical officer of Adamas Pharmaceuticals.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA approved Gocovri extended-release tablets for patients with Parkinson’s disease, marking the product’s second indication in the disease, according to a press release from Adamas Pharmaceuticals, the drug’s manufacturer.

Gocovri (amantadine, Adamas Pharmaceuticals) is now approved as an adjunctive treatment to levodopa/carbidopa in patients with PD who are experiencing off episodes. The drug first received approval for the management of dyskinesia in patients with PD being treated with levodopa-based therapy with or without concomitant dopaminergic agents, according to the release.

Data from two placebo-controlled phase 3 trials demonstrated that amantadine significantly decreased off time as well as dyskinesia in patients with PD, providing a “clinically meaningful increase in good on time” for patients taking a levodopa-based medication. Additionally, the phase 3, open-label EASE LID-2 study demonstrated that amantadine provided sustained efficacy for at least 2 years.

“The extensive clinical trial evidence for [amantadine] supports its unique ability to reduce off episodes and dyskinesia in people with [PD] who are on levodopa/carbidopa therapy,” Adrian Quartel, MD, chief medical officer of Adamas Pharmaceuticals, said in the release. “Many PD medications necessitate a trade-off between reducing off time and exacerbating levodopa-induced dyskinesia. [Amantadine] is the first medication approved to reduce both.”

References: